Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells

International Immunopharmacology

Volumn 28, Issue 1, 2015, Pages 215-219

  Miglio, Gianluca ^a   Veglia, Eleonora ^a   Fantozzi, Roberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Dimethyl fumarate; Macrophages; Pyroptosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRYOPYRIN; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; PARTHENOLIDE; PHORBOL 13 ACETATE 12 MYRISTATE; CARRIER PROTEIN; FUMARIC ACID DERIVATIVE; IL1B PROTEIN, RAT; NLRP3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG HYDROLYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PYROPTOSIS; THERAPY EFFECT; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS;

ADENOSINE TRIPHOSPHATE; CARRIER PROTEINS; CASPASE 1; CELLS, CULTURED; FUMARATES; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MACROPHAGES; PYROPTOSIS; TETRADECANOYLPHORBOL ACETATE;

EID: 84934919900     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.06.011     Document Type: Article

References (20)

1. W. Schweckendiek Behandlung der Psoriasis vulgaris Med. Monatsschr. 13 1959 103 104
2. U. Mrowietz, E. Christophers, and P. Altmeyer Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study Br. J. Dermatol. 138 1998 456 460
3. J.J. Hoefnagel, H.B. Thio, R. Willemze, and J.N. Bouwes Bavinck Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis Br. J. Dermatol. 149 2003 363 369
4. L. Kappos, R. Gold, D.H. Miller, D.G. Macmanus, E. Havrdova, and V. Limmroth Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 372 2008 1463 1472
5. R. Gold, L. Kappos, D.L. Arnold, A. Bar-Or, G. Giovannoni, and K. Selmaj Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N. Engl. J. Med. 367 2012 1098 1107
6. R.J. Fox, D.H. Miller, J.T. Phillips, M. Hutchinson, E. Havrdova, and M. Kita Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N. Engl. J. Med. 367 2012 1087 1097
7. T. Bergsbaken, S.L. Fink, and B.T. Cookson Pyroptosis: host cell death and inflammation Nat. Rev. Microbiol. 7 2009 99 109
8. E. Latz, T.S. Xiao, and A. Stutz Activation and regulation of the inflammasomes Nat. Rev. Immunol. 13 2013 397 411
9. C. Juliana, T. Fernandes-Alnemri, J. Wu, P. Datta, L. Solorzano, and J.W. Yu Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome J. Biol. Chem. 285 2010 9792 9802
10. Y.N. Gong, X. Wang, J. Wang, Z. Yang, S. Li, and J. Yang Chemical probing reveals insights into the signaling mechanism of inflammasome activation Cell Res. 20 2010 1289 1305
11. M. Cocco, D. Garella, A. Di Stilo, E. Borretto, L. Stevanato, and M. Giorgis Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis J. Med. Chem. 57 2014 10366 10382
12. T.J. Schmidt, M. Ak, and U. Mrowietz Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine-preparation of S-substituted thiosuccinic acid esters Bioorg. Med. Chem. 15 2007 333 342
13. A.M. Manuel, and N. Frizzell Adipocyte protein modification by Krebs cycle intermediates and fumarate ester-derived succination Amino Acids 45 2013 1243 1247
14. J.C. Lehmann, J.J. Listopad, C.U. Rentzsch, F.H. Igney, A. von Bonin, and H.H. Hennekes Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1 J. Invest. Dermatol. 127 2007 835 845
15. K. Ghoreschi, J. Brück, C. Kellerer, C. Deng, H. Peng, and O. Rothfuss Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells J. Exp. Med. 208 2011 2291 2303
16. H. Peng, M. Guerau-de-Arellano, V.B. Mehta, Y. Yang, D.J. Huss, and T.L. Papenfuss Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling J. Biol. Chem. 287 2012 28017 28026
17. G. Miglio, A. Romanò, A.D. Sabatino, F. Cordero, M. Beccuti, and M.T. Giraudo The mode of action of dimethyl fumarate: protein succination and anti-pyroptotic effects Pharmacology 2014, London, 16-18 Dec 2014: Proceedings of the British Pharmacological Society 2014 (http://www.pa2online.org/abstracts/vol12issue3abst104p.pdf)
18. C. Nieboer, D. de Hoop, P.N. Langendijk, A.C. van Loenen, and J. Gubbels Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester Dermatologica 181 1990 33 37
19. S. Dibbert, B. Clement, T. Skak-Nielsen, U. Mrowietz, and M. Rostami-Yazdi Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism Arch. Dermatol. Res. 305 2013 447 451
20. J.H. Chewning, and C.T. Weaver Development and survival of Th17 cells within the intestines: the influence of microbiome- and diet-derived signals J. Immunol. 193 2014 4769 4777